Sugi Predict

Sugi Predict / Compounds / SCHEMBL4764247

SCHEMBL4764247

SCHEMBL4764247

Brc1ccc(C2CCOCC2)nc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.41
▸ OPRL1 P41146 1/20 0.41
▸ NOTUM Q6P988 2/20 0.38
▸ AKR1C3 P42330 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ DYRK1A Q13627 2/20 0.35
▸ KDM5B Q9UGL1 1/20 0.34
▸ MAP3K12 Q12852 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551516 1.00 OPRM1 (0.41) OPRM1OPRL1NOTUMAKR1C3TSHR
SCHEMBL30600078 0.86 OPRM1 (0.46) OPRM1OPRL1NOTUM
SCHEMBL588122 0.86 OPRM1 (0.46) OPRM1OPRL1NOTUM
SCHEMBL23148740 0.82 OPRM1 (0.43) OPRM1OPRL1NOTUM
SCHEMBL21841699 0.81 OPRM1 (0.40) OPRM1OPRL1NOTUMAKR1C3TSHR
SCHEMBL15167135 0.78 TRPV3 (0.40) OPRM1OPRL1NOTUMMAPK1
SCHEMBL13724214 0.78 NOTUM (0.38) NOTUMPIK3CDPIK3CADYRK1AKDM5B
SCHEMBL6919321 0.78 MAPK1 (0.46) OPRM1OPRL1NOTUMPIK3CDPIK3CA
SCHEMBL15168141 0.78 MAPK8 (0.42) OPRM1OPRL1NOTUM
SCHEMBL3063348 0.78 OPRM1 (0.41) OPRM1OPRL1NOTUMKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676927-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS Synnovation Therapeutics, Inc. (US) 2026-01-14 — — EP disclosed
EP-4663630-A1 NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR LG Chem, Ltd. (KR) 2025-12-17 — — EP disclosed
US-12286455-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2025-04-29 — — US disclosed
US-20250034162-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-01-30 — — US disclosed
US-12145944-B2 Imidazopyrimidines as EED inhibitors and the use thereof REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-11-19 — — US disclosed
US-20240316051-A1 A PHARMACEUTICAL COMBINATION AND USE THEREOF ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2024-09-26 — — US disclosed
WO-2024187049-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2024-09-12 — — WO disclosed
CN-114127073-B Imidazopyrimidines as EED inhibitors and use thereof 密歇根大学董事会 2024-05-31 — — CN disclosed
CN-115212311-A Pharmaceutical composition and application thereof 苏州亚盛药业有限公司 2022-10-21 — — CN disclosed
CN-114891070-A Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-08-12 — — CN disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 — — US disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 — — US disclosed
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-15 — — US disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 — — EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 — — US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 — — US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 — — US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 — — US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 — — US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211075-A1 AMIDE DERIVATIVE AND USE THEREOF IL2, IL4, IL5 OPRM1 3794/4885OPRL1 3001/4885NOTUM 245/4885
US-20240316051-A1 A PHARMACEUTICAL COMBINATION AND USE THEREOF EED, EML4, KIT OPRM1 4428/4885OPRL1 4022/4885NOTUM 1780/4885
US-12145944-B2 Imidazopyrimidines as EED inhibitors and the use thereof EED, EEF1D, EEF1A1 OPRM1 3482/4885OPRL1 3652/4885NOTUM 4038/4885
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 OPRM1 3811/4885OPRL1 2686/4885NOTUM 2663/4885
US-20250034162-A1 IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF EED, EEF1D, EEF1A1 OPRM1 3482/4885OPRL1 3652/4885NOTUM 4038/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 OPRM1 1431/4885OPRL1 1368/4885NOTUM 4246/4885
US-12286455-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP OPRM1 4701/4885OPRL1 2560/4885NOTUM 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.